Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue: +50.1%
EPS: +147.3%
Free cash flow: +53.5%
Total debt: +0.45%

Quarter to September 2026, against a year earlier

396.86 3.24 −0.81%

Follow MDGL

Alert me

Market cap: $9.3B
P/E: 0.0×
Fwd P/E: −68.8×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. (MDGL) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Madrigal Pharmaceuticals, Inc. (MDGL) trades at a P/B ratio of 18.7×. Over the past ten years it has ranged from 0.0× (March 2016) to 475× (December 2022); the current reading is higher than 81% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/MDGL/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Madrigal Pharmaceuticals, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/MDGL/metrics/pb-ratio">Madrigal Pharmaceuticals, Inc. (MDGL) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	21.7×	149.12%
FY2024	8.7×	—

Period	P/B ratio	Change
Sep 2026	23.5×	(21.32%)
Jun 2026	29.9×	6.85%
Mar 2026	28.0×	29.01%
Dec 2025	21.7×	3.73%
6 more quarters	Free account

Against its own ten years

Low 0.0× High 475×

Ten-year median 6.5×

Current reading's percentile 78

Company	P/B ratio
CYTK Cytokinetics, Incorporated compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
KRYS Krystal Biotech, Inc. compare	6.2×
SYRE Spyre Therapeutics, Inc. compare	9.5×
PTGX Protagonist Therapeutics, Inc. compare	10.6×
CAI Caris Life Sciences,�Inc. compare	12.7×
TGTX TG Therapeutics, Inc. compare	13.6×
TWST Twist Bioscience Corporation compare	17.1×
MDGL Madrigal Pharmaceuticals, Inc.	18.7×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Madrigal Pharmaceuticals, Inc. (MDGL) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on MDGL

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on MDGL

Stockrow Weekly